A Comprehensive Dosimetric and Plan Quality Evaluation of Non-coplanar VMAT With Flattening Filter-free Versus Flattened Beams for Hippocampal-Avoidance Whole-Brain Radiotherapy: A Multi-Platform Study on Elekta Infinity and UIH uRT-Linac Systems
Technology in Cancer Research & Treatment · 2026-07 · 25
DOI: 10.1177/15330338261467841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 10.07.2026. Verfasst von Xiao-Long Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiophysics, Zhejiang Cancer Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Radiotherapy Planning, Computer-Assisted, Brain Neoplasms, Hippocampus, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Zhejiang Medicine and Health Science and Technology Plan Project.
Abstract (Originalsprache)
Introduction
Hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) effectively reduces neurocognitive decline in patients with brain metastases, but evidence from direct multi-platform comparisons remains limited. This study addresses the gap by comparing two mainstream radiotherapy systems for non-coplanar VMAT (NCVMAT) with flattening filter-free (FFF) and flattened (FF) beams.
Methods
A retrospective dosimetric cohort study was conducted on 22 consecutive patients. Four plan types were created: MC-NCVMAT (Elekta Infinity/Monaco) FFF/FF and UT-NCVMAT (UIH uRT-linac 506c/uRT-TPOIS) FFF/FF. Dosimetry, organ-at-risk (OAR) sparing, efficiency, and plan quality metric (PQM) were evaluated. Identical constraints were applied across platforms.
Results
UT-NCVMAT showed significantly better homogeneity, conformity, and OAR sparing than MC-NCVMAT. FFF beams outperformed FF in hippocampal protection. UT-NCVMAT reduced beam-on time and planning time by 44%. The 16-item PQM score was significantly higher in the UIH group. Post-hoc power analysis confirmed sample adequacy.
Conclusion
The UIH uRT-TPOIS system with NCVMAT FFF may offer superior dosimetry, efficiency, and clinical feasibility for HA-WBRT. The PQM model may serve as a reliable tool for standardized plan evaluation. Further multi-center validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiophysics, Zhejiang Cancer Hospital, Hangzhou, China.
- Department of Radiotherapy, The First People's Hospital of Aksu Prefecture, China.
- Department of Radiotherapy, Quzhou City People's Hospital, Quzhou, China.
ORCID-Profile: Xiao-Long Cheng
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Zhejiang Medicine and Health Science and Technology Plan Project
Zitieren
APA
Cheng, X. L., Zhang, L., Sun, L., & Yu, W. L. (2026). A Comprehensive Dosimetric and Plan Quality Evaluation of Non-coplanar VMAT With Flattening Filter-free Versus Flattened Beams for Hippocampal-Avoidance Whole-Brain Radiotherapy: A Multi-Platform Study on Elekta Infinity and UIH uRT-Linac Systems. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261467841
Vancouver
Cheng XL, Zhang L, Sun L, Yu WL. A Comprehensive Dosimetric and Plan Quality Evaluation of Non-coplanar VMAT With Flattening Filter-free Versus Flattened Beams for Hippocampal-Avoidance Whole-Brain Radiotherapy: A Multi-Platform Study on Elekta Infinity and UIH uRT-Linac Systems. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261467841
BibTeX
@article{Cheng2026,
author = {Cheng, Xiao-Long and Zhang, Lu and Sun, Long and Yu, Wen-Liang},
title = {A Comprehensive Dosimetric and Plan Quality Evaluation of Non-coplanar VMAT With Flattening Filter-free Versus Flattened Beams for Hippocampal-Avoidance Whole-Brain Radiotherapy: A Multi-Platform Study on Elekta Infinity and UIH uRT-Linac Systems},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261467841}
}
EUVIMED